KFA Private Wealth Group LLC Acquires 1,567 Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• KFA Private Wealth Group LLC increased its holdings in Johnson & Johnson by 48.0% in Q1, bringing its total to 4,833 shares valued at approximately $802,000.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, resulting in an annualized dividend yield of 3.09%.
• The company's quarterly earnings report revealed an EPS of $2.77, exceeding expectations, with revenues totaling $23.74 billion—a 5.8% year-over-year increase.

KFA Private Wealth Group LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 48.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,833 shares of the company's stock after buying an additional 1,567 shares during the quarter. KFA Private Wealth Group LLC's holdings in Johnson & Johnson were worth $802,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Conquis Financial LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $33,000. Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $36,000. Highline Wealth Partners LLC grew its position in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Finally, Capital A Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $50,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on JNJ. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Barclays boosted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Morgan Stanley upped their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Finally, Raymond James Financial cut their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $174.50.

Johnson & Johnson Trading Down 1.4%

NYSE JNJ traded down $2.30 on Thursday, reaching $164.96. The company had a trading volume of 3,882,115 shares, compared to its average volume of 9,023,639. The firm has a market cap of $397.27 billion, a price-to-earnings ratio of 17.70, a P/E/G ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The business has a 50 day moving average of $156.93 and a two-hundred day moving average of $156.30. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the prior year, the business posted $2.82 earnings per share. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.15%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.